Metagenomi Therapeutics, Inc.
MGX
$1.46
-$0.02-1.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -10.47% | -2.44% | 20.49% | -7.01% | -24.64% |
| Total Depreciation and Amortization | -1.81% | -0.82% | -1.69% | -7.05% | 7.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.76% | -34.34% | 68.66% | -71.96% | 234.35% |
| Change in Net Operating Assets | -10.81% | 28.97% | -248.33% | 85.26% | -23.12% |
| Cash from Operations | -10.79% | -0.01% | 6.97% | 13.07% | 1.36% |
| Capital Expenditure | -14.86% | 41.73% | 55.90% | 13.77% | 72.17% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.27% | 43.18% | -23.40% | -13.38% | 473.40% |
| Cash from Investing | 18.28% | 43.47% | -22.87% | -13.37% | 419.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 89.84% | 32.00% | -257.14% | -- | -- |
| Cash from Financing | 139.57% | -12.65% | -115.58% | -- | 100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 50.16% | 352.58% | -229.63% | -20.27% | 106.29% |